“Global Biomarkers Market set to grow to 57bn by 2024” says Visiongain report

12 February 2019
Pharma

Visiongain has published a new pharma report Global Biomarkers Market Forecast to 2029: Consumables, Services, Software, Biomarker Discovery, Biomarker Diagnostics, Biomarker Services, Safety Biomarkers, Efficacy Biomarkers, Validation Biomarkers, Genomics, Proteomics, Bioinformatics, Cancer, Cardiovascular Diseases, CNS Diseases, Autoimmune Diseases.

The use of biomarkers in drug development, including as surrogate endpoints for clinical trials, is rapidly gaining acceptance within the pharmaceutical industry and with regulatory bodies. A great deal of research has been performed in the past decade alone for the discovery of disease biomarkers, identifying new drug targets, as well indicators for treatment response. This field is being driven by increased investment by pharmaceutical companies and academia, as well non-profit organisations.

This report profiled the selected companies: AB SCIEX, Abbott Laboratories, Agilent, AstraZeneca, Axela Inc, Caprion Proteomics, Charles River Laboratories, Critical Diagnostics, Epigenomics and others.

The analyst commented that "The increased demand for diagnostic tests that will identify patients who are most likely to respond to treatment will be a key factor in the growth of this sector. The biomarker discovery sector will also grow strongly, as a result of increased interest in biomarker research within the pharmaceutical industry. Future growth in the genomic biomarkers market will be driven by progress in mapping the genome of specific diseases."

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Human Microbiome Therapeutics market set to grow to $1.6bn” by 2025 says new Visiongain report

The market for microbiome therapeutics is expected to commence around mid-2020 with the launch of new products relating to dermatology and gastrointestinal disorders.

04 December 2019

Read

“Global Next-Generation Biologics market set to grow to $42bn by 2024” says new Visiongain report

Technological developments in the next-generation biologics market will be the result of clinical development of multiple platforms in the next-generation antibody, antibody fragment and ALP sectors.

04 December 2019

Read

“Global Liquid Biopsy market set to grow to $4.9bn by 2024” says new Visiongain report

The main drivers for the growth include technological advancements such as development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

04 December 2019

Read

“Global nucleic acid isolation and purification market is anticipated to reach USD 8.16 Billion by 2030”, says Visiongain

Nucleic acid separation and purification is one of modern science and technology’s most complex and critical accomplishments.

29 November 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever